We are live on ! Find out more
ACM

Aquilo Capital Management Portfolio holdings

AUM $55.8M
1-Year Est. Return 41.76%
This Fund
S&P 500
This Quarter Est. Return
+37.36%
1 Year Est. Return
-41.76%
3 Year Est. Return
-6.84%
5 Year Est. Return
+20.73%
10 Year Est. Return
–
AUM
$496M
AUM Growth
+$239M
Cap. Flow
+$135M
Cap. Flow %
27.22%
Top 10 Hldgs %
93.06%
Holding
16
New
2
Increased
8
Reduced
–
Closed
2

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$21.3M
2
QURE icon
uniQure
QURE
+$10.5M
3
RGNX icon
Regenxbio
RGNX
+$10.4M
4
ARGX icon
argenx
ARGX
+$6.35M
5
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$4.68M

Top Sells

Rank Stock Value
1
XENE icon
Xenon Pharmaceuticals
XENE
+$17M
2
MRUS
Merus
MRUS
+$9.32M

Sector Composition

Rank Sector Weight
1 Healthcare 47.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$224M 45.15%
2,000,000
+1,000,000
+100% +$98.5M
DRNA
2
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$36.9M 7.45%
1,454,686
+217,307
+18% +$4.68M
ANAB icon
3
AnaptysBio
ANAB
$1.68B
$35.5M 7.17%
1,590,733
+151,654
+11% +$2.77M
QURE icon
4
uniQure
QURE
$3.22B
$30.6M 6.18%
679,620
+177,645
+35% +$10.5M
SPRO icon
5
Spero Therapeutics
SPRO
$73M
$26.3M 5.3%
1,943,081
+124,941
+7% +$1.4M
BPMC
6
DELISTED
Blueprint Medicines
BPMC
$24.6M 4.95%
+315,029
New +$21.3M
ARWR icon
7
Arrowhead Research
ARWR
$12.4B
$24.3M 4.91%
563,291
+126,777
+29% +$4.47M
NGM
8
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$21.6M 4.36%
1,095,184
+48,000
+5% +$917K
RGNX icon
9
Regenxbio
RGNX
$708M
$20.4M 4.11%
553,453
+280,242
+103% +$10.4M
PVLA
10
Palvella Therapeutics
PVLA
$2.27B
$17.3M 3.49%
69,694
– –
PRQR icon
11
ProQR Therapeutics
PRQR
$265M
$14.6M 2.94%
2,401,570
– –
LKFT
12
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.77B
$8.73M 1.76%
44,234
– –
ARGX icon
13
argenx
ARGX
$54.1B
$8.06M 1.63%
+35,800
New +$6.35M
MOR
14
DELISTED
MorphoSys AG American Depositary Shares
MOR
$3.04M 0.61%
95,898
– –
MRUS
15
DELISTED
Merus
MRUS
– –
-770,183
Closed -$9.32M
XENE icon
16
Xenon Pharmaceuticals
XENE
$6.12B
– –
-1,499,970
Closed -$17M

Similar funds

VCM
VeriStar Capital Management New York $54.7M AUM 2.08% 1-Year Est. Return
YEPV
Yorktown Energy Partners VIII New York $52.9M AUM 30% 1-Year Est. Return
HWP
Heritage Wealth Partners Dublin, Ohio $65.6M AUM 16.69% 1-Year Est. Return
GIS
Grayhawk Investment Strategies Calgary, Alberta, Canada $43.9M AUM 6.23% 1-Year Est. Return
AA
AlphaQ Advisors Winter Park, Florida $41.7M AUM 12.96% 1-Year Est. Return
PGIM
Pacific Global Investment Management Glendale, California $70.7M AUM 14.46% 1-Year Est. Return
RGMC
Revolution Growth Management Company Washington, District of Columbia $70.8M AUM 20.1% 1-Year Est. Return
PAM
Pamalican Asset Management Hong Kong $75.4M AUM

Aquilo Capital Management's Q2 2020 Portfolio in Review

As of Q2 2020, Aquilo Capital Management held 16 positions worth $496M, up 93% from $257M the previous quarter. Its ten largest holdings account for 93% of the portfolio.

Aquilo Capital Management deployed $135M of net new capital in Q2 2020, opening 2 new positions and adding to 8 existing holdings. Its largest new stake was Blueprint Medicines: 315,029 shares worth $24.6M.

By sector, the portfolio is most concentrated in Healthcare at 47% of assets, down from 61% a quarter earlier.

On the sell side, the most notable exit was Xenon Pharmaceuticals, an estimated $17M sold.

  • Aquilo Capital Management's largest Q2 2020 buy was Blueprint Medicines: 315,029 shares worth $24.6M.
  • Aquilo Capital Management added most to uniQure in Q2 2020, an estimated $10.5M increase.
  • Aquilo Capital Management fully exited Xenon Pharmaceuticals in Q2 2020, selling an estimated $17M.
  • Aquilo Capital Management's ten largest holdings make up 93% of its $496M portfolio in Q2 2020.
  • Aquilo Capital Management opened 2 new positions and closed 2 in Q2 2020.
  • Aquilo Capital Management's portfolio value rose 93% quarter-over-quarter to $496M.

Based on Aquilo Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.